Thromb Haemost 1991; 66(05): 552-558
DOI: 10.1055/s-0038-1646458
Original Article
Schattauer GmbH Stuttgart

Discordant Expression of Tissue Factor Antigen and Procoagulant Activity on Human Monocytes Activated with LPS and Low Dose Cycloheximide

John D Walsh
The Heart Research Institute, Camperdown, N.S.W., Australia
,
Carolyn L Geczy
The Heart Research Institute, Camperdown, N.S.W., Australia
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 20. August 1990

Accepted 17. Mai 1991

Publikationsdatum:
25. Juli 2018 (online)

Summary

The mechanisms underlying the superinduction of procoagulant activity by cycloheximide (CHX) on LPS-activated human monocytes have been investigated. Tissue factor (TF) activity of intact, viable cells was quantitated with a plasma recalcification assay and assays using chromogenic substrates specific for thrombin and factor Xa (FXa). TF antigen was measured simultaneously by immunocytochemical staining and immunoblotting with an anti-TF monoclonal antibody (MAb). Peripheral blood mononuclear cells (PBMC) activated with LPS in the presence of low dose CHX expressed more TF activity (approx. 100% increase) than cells activated with LPS alone. However, TF antigen levels were decreased approximately 70% by CHX. This discordant relationship was due primarily to differences in rates of activation of factor X (FX); LPS/CHX-treated PBMC activated nearly twice as much FX as LPS-treated cells (2.19 ± 0.37 versus 1.10 ± 0.21 ng FXa/106 PBMC/min, respectively). These studies indicate that TF cofactor activity on LPS/CHX-treated monocytes was approximately 7 times greater than that present on LPS-treated cells. Increased TF functional activity may be due to CHX-induced alterations in the type and content of phospholipids (PL) in the cell membrane. Results showed that exogenous mixed PL markedly increased TF activity on LPS-activated monocytes, but not on LPS/CHX-activated cells, without increasing TF antigen levels or altering cell viability. Membrane alterations may occur on monocytes in certain pathological or iatrogenic conditions resulting in a highly active form of TF in vivo.

 
  • References

  • 1 Carson S. Continuous chromogenic tissue factor assay - comparison to clot-based assays and sensitivity established using pure tissue factor. Thromb Res 1987; 47: 379-87
  • 2 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 1-8
  • 3 Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-51
  • 4 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JR. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa – insight into its possible mechanism of action. Blood 1988; 71: 335-43
  • 5 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues – implications for disorders of haemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97
  • 6 Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975; Vol 30: 311-6
  • 7 Ryan J, Geczy CL. Characterisation and purification of mouse macrophage procoagulant-inducing factor. J Immunol 1986; 137: 2864-70
  • 8 Gregory SA, Kornbluth RS, Helin H, Remold HG, Edington TS. Monocyte procoagulant inducing factor-a lymphokine involved in the T cell instructed monocyte procoagulant response to antigen. J Immunol 1986; 137: 3231-9
  • 9 Rothberger H, Zimmerman TS, Spiegelberg HL, Vaughan JH. Leukocyte procoagulant activity-enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest 1977; 59: 549-57
  • 10 Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leukocyte production of tissue factor activity. J Clin Invest 1979; 63: 147-50
  • 11 Edgington TS, Taylor F, Chang A, Ruf W, Morrissey JH, Blick K. Arrest of cellular initiation of coagulation in vivo by anti-tissue factor monoclonal antibody prevents lethal septic shock. Thromb Haemostas (Abstr) 1989; 62: 347
  • 12 Warr TA, Rao LVM, Rapaport SI. The role of tissue factor (TF) in endotoxin-induced disseminated intravascular coagulation (DIC) in rabbits. Thromb Haemostas (Abstr) 1989; 74: 94a
  • 13 Wilcox JN, Hasko JA, Deisher TA, Bunting S. Identification of cells expressing tissue factor mRNA by in situ hybridization after in vivo administration of endotoxin to rats. Thromb Haemostas (Abstr) 1989; 62: 348
  • 14 Lyberg T. Chemical significance of increased thromboplastin activity on the monocyte surface – a brief review. Haemostasis 1984; 14: 430-9
  • 15 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles - induction of co-operativity by phosphatidylserine. Biochemistry 1986; 25: 4007-20
  • 16 Graminski RA, Broze Jr GJ, Carson SD. Human fibroblast tissue factor is inhibited by lipoprotein-associated coagulation inhibitor and placental anticoagulant protein but not by apolipoprotein A-II. Blood 1989; 73: 983-9
  • 17 Schorer AE, Rick PD, Swaim WR, Moldow CF. Structural features of endotoxin required for stimulation of endothelial cell tissue factor production; exposure of preformed tissue factor after oxidant-mediated endothelial cell injury. J Lab Clin Med 1985; 106: 38-42
  • 18 Maynard JR, Heckman CA, Pitlick FA, Nemerson Y. Association of tissue factor activity with the surface of cultured cells. J Clin Invest 1975; 55: 814-24
  • 19 Drake TA, Ruf W, Morrisey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-95
  • 20 Wheeler HR, Geczy CL. Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer, in press.
  • 21 Carson SD, Ross SE, Bach R, Guha A. An inhibiting monoclonal antibody against human tissue factor. Blood 1987; 70: 490-3
  • 22 Levy GA, Schwartz BS, Edgington TS. The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide. J Immunol 1981; 127: 357-63
  • 23 Geczy C, Raper R, Roberts IM, Myer P, Bernard CCA. Macrophage procoagulant activity as a measure of cell-mediated immunity to P2 protein of peripheral nerves in the Guillain-Barre Syndrome. J Neuroimmunol 1985; 9: 179-91
  • 24 Lando PA, Biazak CE, Edgington TS. Amidolytic assay for procoagulant activity of lymphoid and tumor cells. J Immunol Meth 1986; 89: 131-9
  • 25 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 . Nature (London) 1970; 227: 680-5
  • 26 Ryan J, Geczy C. Coagulation and the expression of cell-mediated immunity. Immunol Cell Biol 1987; 65: 127-39
  • 27 Arend WP, D'Angelo S, Joslin FG. Regulation of interleukin 1 production in human monocytes 1. Effects of y-interferon and cycloheximide. Clin Exp Immunol 1988; 74: 377-81
  • 28 Collart MA, Belin D, Vassalli JD, de Kossoda S, Vassalli P. Interferon enhances macrophage transcription of tumor necrosis factor/cachectin, interleukin 1 and urokinase genes, which are controlled by short-lived repressors. J Exp Med 1986; 164: 2113-8
  • 29 Ringold GM, Dickman B, Vannice JL, Trahey M, McCormick F. Inhibition of protein synthesis stimulated the transcription of human β-interferon genes in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1984; 81: 3964-8
  • 30 Hamilton RT, Nilsen-Hamilton M, Adams G. Superinduction by cycloheximide of mitogen-induced secreted proteins by Balb/c 3T3 cells. J Cell Physiol 1985; 123: 201-8
  • 31 Efrat S, Kaempfer R. Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes. Proc Natl Acad Sci USA 1984; 81: 2601-5
  • 32 Moon DK, Geczy CL. Recombinant IFNγ synergizes with lipopolysaccharide to induce macrophage membrane procoagulants. J Immunol 1988; 141: 1536-42
  • 33 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 2752-5
  • 34 Broze Jr GJ. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-35
  • 35 Noguchi M, Sakai T, Kisiel W. Correlation between antigenic and functional expression of tissue factor on the surface of cultured human endothelial cells following stimulation by lipopolysaccharide endotoxin. Thromb Res 1989; 55: 87-97
  • 36 Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational change. Biochemistry 1986; 25: 4020-33
  • 37 Bangham AD. A correlation between surface charge and coagulant action of phospholipids. Nature 1961; 192: 1197-8
  • 38 Mann KG. The assembly of blood clotting complexes on membranes. TIBS 1987; 12: 229-33
  • 39 Rothman J, Lenard J. Membrane asymmetry. Science 1977; 195: 743-53
  • 40 Bevers EM, Comfurious P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983; 736: 57-66
  • 41 Connor J, Bucana C, Fidler IJ, Schroit AJ. Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: Quantitative assessment of outer-leaflet lipid by prothrombinase complex formation. Proc Natl Acad Sci USA 1989; 86: 3184-8
  • 42 Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-9